



**Miragen Therapeutics to Present a Corporate Overview at the Robert W Baird & Co. 2019 Global Healthcare Conference**

**BOULDER, CO, August 15, 2019** - miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Robert W. Baird & Co. 2019 Global Healthcare Conference, which is taking place on September 4-5 New York City.

**Robert W. Baird & Co. 2019 Global Healthcare Conference**

Date: Thursday, September 5  
Time: 8:30 a.m. Eastern Time  
Webcast: <http://wsw.com/webcast/baird56/mgen/>

The presentation will be webcast live and may also be accessed by visiting the "Investors & Media" section of the Company's web site at [www.miragen.com](http://www.miragen.com). A replay of the webcast will be available for 90 days after the event.

**About miRagen Therapeutics, Inc.**

miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen, remlarsen, and MRG-110. miRagen's clinical product candidate for the treatment of certain cancers, cobomarsen, is an inhibitor of microRNA-155, which is found at abnormally high levels in malignant cells of several blood cancers. miRagen's clinical product candidate for the treatment of pathological fibrosis, remlarsen, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as in systemic sclerosis. MRG-110, an inhibitor of microRNA-92, is being developed for the treatment of heart failure and other ischemic disease. In addition to these programs, miRagen is developing a pipeline of preclinical product candidates. The goal of miRagen's translational medicine strategy is to progress rapidly to first-in-human studies once it has established the pharmacokinetics, pharmacodynamic, safety, and manufacturability of the product candidate in preclinical studies. For more information, please visit [www.miragen.com](http://www.miragen.com).

For information on clinical trials please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

**Investor/Media Contact:**

Dan Ferry  
Managing Director  
LifeSci Advisors, LLC  
(617) 535-7746